Roche licenses antibiotic from Meiji, Fedora
Meiji Seika Pharma Co. Ltd. (Tokyo, Japan) and Fedora Pharmaceuticals Inc. (Edmonton, Alberta) granted Roche (SIX:ROG; OTCQX:RHHBY) exclusive, worldwide rights outside of Japan to develop and commercialize OP0595 (FPI-1459), a beta-lactamase inhibitor in Phase I testing. Meiji and Fedora are eligible to receive up to $750 million in an upfront payment and milestones, plus tiered royalties. Meiji will retain rights in Japan.
Roche spokesperson Stepan Kracala said the company plans to study OP0595 combined with beta-lactam antibiotics in patients with complicated urinary tract infections (cUTIs), complicated intra-abdominal infections (cIAI), hospital acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) caused by Enterobacteriaceae, including multi-drug resistant strains. Kracala declined to disclose a development timeline. ...